Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors
Status:
Recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study,
evaluating the safety tolerability, PK, preliminary antitumor activity, and effect of
biomarkers of XL092 administered alone, and in combination with nivolumab (doublet),
nivolumab + ipilimumab (triplet), and nivolumab + bempegaldesleukin (triplet) in subjects
with advanced solid tumors.
In the Expansion Stage, the safety and efficacy of XL092 as combination therapy will be
further evaluated in tumor-specific Expansion Cohorts, which will enroll subjects with
genitourinary cancers.